基因组中存在的各种潜在的G-四链体形成序列为通过稳定分子调节其功能提供了平台。尽管G-四链体结构表现出不同的结构拓扑结构,但作为常见结构元素的G-四链体的存在使拓扑结构特异性配体的设计成为一项艰巨的任务。为了解决这个问题,可以利用四重结构中存在的回路和凹槽的细微结构变化。为此,我们报告了基于吡啶,1,8-萘啶和1,10-菲咯啉的双苯并咪唑羧酰胺衍生物的四链体稳定剂的设计和合成。设计的配体可特异性结合并稳定具有在任何人类端粒四链体拓扑结构(平行,杂交,或反平行)和双链DNA。CD熔解研究表明,配体可以赋予更高的稳定性的c-MYC和c-KIT启动子四链(高达21℃的增量在Ť米)比端粒和双工的DNA(Δ Ť米≤2.5℃)。与CD熔解研究一致,配体与c-MYC四链DNA牢固结合( K b =〜10 4至10 5 M –1)。分子建模和动力学研究提供了洞察如何实现特异性的见解,并强调了柔性N的重要性
基因组中存在的各种潜在的G-四链体形成序列为通过稳定分子调节其功能提供了平台。尽管G-四链体结构表现出不同的结构拓扑结构,但作为常见结构元素的G-四链体的存在使拓扑结构特异性配体的设计成为一项艰巨的任务。为了解决这个问题,可以利用四重结构中存在的回路和凹槽的细微结构变化。为此,我们报告了基于吡啶,1,8-萘啶和1,10-菲咯啉的双苯并咪唑羧酰胺衍生物的四链体稳定剂的设计和合成。设计的配体可特异性结合并稳定具有在任何人类端粒四链体拓扑结构(平行,杂交,或反平行)和双链DNA。CD熔解研究表明,配体可以赋予更高的稳定性的c-MYC和c-KIT启动子四链(高达21℃的增量在Ť米)比端粒和双工的DNA(Δ Ť米≤2.5℃)。与CD熔解研究一致,配体与c-MYC四链DNA牢固结合( K b =〜10 4至10 5 M –1)。分子建模和动力学研究提供了洞察如何实现特异性的见解,并强调了柔性N的重要性
[EN] HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONTENANT UN COEUR INDOLE
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2011071716A1
公开(公告)日:2011-06-16
Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.
Targeting the KRAS oncogene: Synthesis, physicochemical and biological evaluation of novel G-Quadruplex DNA binders
作者:Federica D'Aria、Vincenzo Maria D'Amore、Francesco Saverio Di Leva、Jussara Amato、Marco Caterino、Pasquale Russomanno、Silvia Salerno、Elisabetta Barresi、Marinella De Leo、Anna Maria Marini、Sabrina Taliani、Federico Da Settimo、Gilmar F. Salgado、Luca Pompili、Pasquale Zizza、Senji Shirasawa、Ettore Novellino、Annamaria Biroccio、Luciana Marinelli、Concetta Giancola
DOI:10.1016/j.ejps.2020.105337
日期:2020.6
pancreatic, lung and colorectal cancers, thereby representing a relevant target for the treatment of these diseases. The KRAS P1 promoter contains a nuclease hypersensitive, guanine-rich sequence able to fold into a G-quadruplex motif (G4). The stabilization of this G4 structure by small molecules is emerging as a feasible approach to downregulate KRAS expression. Here, a set of novel stabilizing molecules
New fluorogenic chemosensors derived from benzimidazole
作者:Karina S. Tikhomirova、Ivan E. Tolpygin、Andrey G. Starikov、Maria A. Kaz’mina
DOI:10.1007/s10593-017-2037-5
日期:2017.2
synthesis of new 1-substituted N-(anthracen-9-ylmethyl)-1H-benzimidazol-2-amines and 1,2,3-trisubstituted 1H-benzimidazolium chlorides containing anthracene fluorophores. Benzimidazol-2-amine derivatives exhibited high chemosensing activity toward H+ cations, but in neutral media – toward Zn2+ and Cd2+ cations. The quinoline-containing benzimidazolium chloride showed fluorogenic sensor properties toward
Synthesis of pyrimido[1,2-<i>a</i>]benzimidazol-4(10<i>H</i>)-one derivatives and evaluation of their interactions with DNA
作者:A. Da Settimo、G. Primofiore、F. Da Settimo、A. M. Marini、S. Taliani、S. Salerno、L. Dalla Via
DOI:10.1002/jhet.5570400620
日期:2003.11
The synthesis of new derivatives of the planar tricyclic pyrimido[1,2-a]benzimidazole system featuring protonable sidechains in the 3 and/or 10 positions is described. The reported literature procedures for the preparation of the intermediate 3-ethoxycarbonylpyrimido[1,2-a]benzimidazol-4(10H)-one 15, starting from 2-aminobenzimidazole 18 and diethyl ethoxymethylenemalonate, were revised. The interaction
描述了平面三环嘧啶并[1,2- a ]苯并咪唑体系新衍生物的合成,该衍生物在3和/或10位具有质子化侧链。修改了从2-氨基苯并咪唑18和乙氧基亚甲基丙二酸二乙酯开始制备中间体3-乙氧基羰基嘧啶并[1,2- a ]苯并咪唑-4(10 H)-one 15的文献报道方法。初步研究了与DNA的相互作用,固有结合常数以及多种化合物(1–8,10,11)的抗增殖活性。
BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS
申请人:Seth Punit P.
公开号:US20100130513A1
公开(公告)日:2010-05-27
Provided are compounds of the formula:
wherein R
N1
is a substituent of formula G
1
-NX
1
X
2
, wherein G
1
is an optionally further substituted alkylene, which optionally forms, together with R
N2
, a cyclic group, and each of X
1
and X
2
is independently H or an N-substituent, or X
1
and X
2
together form a heterocyclic ring, or X
1
together with G
1
forms a cyclic group and X
2
is H or an N-substituent; and each of Z
1
, Z
2
, Z
3
and Z
4
is H or a substituent, or two of Z
1
, Z
2
, Z
3
and Z
4
together form an optionally substituted ring, and further wherein at least one of Z
1
, Z
2
, Z
3
and Z
4
is other than H, and salts thereof, pharmaceutical compositions and methods of using the compounds. The compounds have antiviral activity.